| Name | LHF-535 |
| Description | LHF-535 is an antiviral compound. It has EC50s of <1 μM, <1 μM, <1 μM, and 1-10 μM for Lassa, Machupo, Junin, and VSVg virus, respectively. |
| In vitro | LHF-535 is a small-molecule viral entry inhibitor that targets the arenavirus envelope glycoprotein (GP). LHF-535 inhibits Lassa GP-pseudotyped lentivirus (IC50: 0.1-0.3 nM). LHF-535 shows effective antiviral activity against a broad array of hemorrhagic fever arenaviruses [2]. |
| In vivo | An increase in survival is also observed when the first dose of LHF-535 (10 mg/kg) is delayed by 1, 2, or 3 days after infection. LHF-535 (3, 10 or 30 mg/kg; orally; daily; 14 days) protects mice from a lethal challenge with Tacaribe virus and dramatically reduces viral titers in plasma, spleen, and liver [2]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 3.3 mg/mL (8 mM), Sonication is recommended. DMSO : 96.67 mg/mL (234.34 mM), Sonication is recommended. H2O : < 0.1 mg/mL (insoluble)
|
| Keywords | VirusProtease | Virus Protease | LHF-535 | LHF535 | LHF 535 | Inhibitor | inhibit | Arenavirus | antiviral |
| Inhibitors Related | Rifampicin | Esculin | Phenytoin sodium | Hexane-2,5-dione | L-Lysine | L-Lysine hydrochloride | Sodium formate | Penicillin G potassium | Ofloxacin | Vidarabine | (E)-3-(p-Tolyl)acrylaldehyde | Thymidine |
| Related Compound Libraries | Bioactive Compound Library | ReFRAME Related Library | Drug Repurposing Compound Library | Anti-Viral Compound Library | NO PAINS Compound Library | Orally Active Compound Library | Immunology/Inflammation Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Anti-Infection Compound Library |